Clinical Trials

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer


Study ID
NRG Oncology BR003

NCT Number
NCT02488967 (Click on the NCT number for more information about the trial)

Research Study Number
5952

Principle Investigator
Dr. Donna McNamara

Phase
III

Sponsor
NRG Oncology


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now